Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tatemachi, 1163, 193-0998, Hachioji, Tokyo, Japan.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
BMC Ophthalmol. 2022 Jun 4;22(1):247. doi: 10.1186/s12886-022-02478-9.
Patients with central retinal vein occlusion (CRVO) and macular edema often are treated by intravitreal ranibizumab injection (IRI). The role of changes in macular sensitivity in the positive effects of IRI on visual functions is unclear. Therefore, we assessed the relationship between macular sensitivity and improvement of visual functions.
We included 15 eyes of 15 patients with treatment-naïve CRVO and followed patients for 6 months after pro re nata IRI. IRI was repeated if the central macular thickness was greater than or equal to 300 µm. Microperimetry-3 was used to measure macular sensitivity within the central 1-mm, 3-mm, and 6-mm fields before and monthly for 6 months after IRI.
IRI significantly improved mean macular sensitivity over time within the central 1-mm, 3-mm, and 6-mm fields (all P < 0.001). None of the fields showed significant differences in the change of mean macular sensitivity between patients with little improvement in best corrected visual acuity (BCVA; i.e., in patients with a change in logarithm of the minimum angle of resolution [logMAR] BCVA < 0.3) and those with marked improvement in BCVA (change in logMAR BCVA > 0.3). The mean macular sensitivity before IRI showed correlations with the improvement of macular sensitivity in every field.
These findings suggest that IRI improves macular sensitivity in patients with CRVO and macular edema independent of any improvement in BCVA and that macular sensitivity before treatment is associated with improvement of macular sensitivity after treatment.
患有视网膜中央静脉阻塞（CRVO）和黄斑水肿的患者常接受玻璃体内雷珠单抗注射（IRI）治疗。IRI 对视觉功能的积极影响中，黄斑敏感性变化的作用尚不清楚。因此，我们评估了黄斑敏感性与视觉功能改善之间的关系。
我们纳入了 15 例 15 只未经治疗的 CRVO 患者，并在 IRI 后 6 个月内对患者进行随访。如果中央黄斑厚度大于或等于 300μm，则重复 IRI。在 IRI 前和 IRI 后每月进行一次，使用微视野计-3 测量中央 1mm、3mm 和 6mm 范围内的黄斑敏感性。
IRI 显著改善了中央 1mm、3mm 和 6mm 范围内黄斑敏感性的平均值，且随时间推移差异均有统计学意义（均 P<0.001）。在最佳矫正视力（BCVA；即 logMAR BCVA 变化<0.3 的患者和 BCVA 显著改善的患者（logMAR BCVA 变化>0.3）中，各视野中平均黄斑敏感性变化无显著差异。IRI 前的平均黄斑敏感性与各视野中黄斑敏感性的改善均相关。
这些发现表明，IRI 可改善 CRVO 和黄斑水肿患者的黄斑敏感性，与 BCVA 的任何改善无关，并且治疗前的黄斑敏感性与治疗后的黄斑敏感性改善相关。
